Journal of Medical and Health Studies (JMHS)
ISSN: 2710-1452
DOI: 10.32996/jmhs
Journal Homepage: www.al-kindipublisher.com/index.php/jmhs

JMHS
AL-KINDI CENTER FOR RESEARCH AND DEVELOPMENT

| RESEARCH ARTICLE

A Novel Multi-Stage Pressure-Responsive Glaucoma Valve Strip for Anterior Chamber Angle Implantation: A Futuristic Approach to Precision IOP Control

Prof. Dr. Aurangzeb Shaikh, FRCS (Glasgow, Edinbrough, London), FCPS, MCPS, MSc PH (LSHTM), Fellow RSPH, Member AoME.
Dr Jahangir Shaikh MBBS. MPH Student at Ziauddin University Sukkur Campus.
Ali zeb MBBS 4th Year Student at Ziauddin University Karachi.
Anjali Zeb 2nd Year BDS Student at Ziauddin University Karachi
Dr Ayesha Zeb (Medical Officer) The Eye Clinic Clifton.
Mr Raj Kumar Optometrist,FRPMC Karachi

Corresponding Author: Professor Dr. Aurangzeb Shaikh, **E-mail**: zebshaikh@hotmail.com

| ABSTRACT
This paper introduces a novel concept for surgical glaucoma management: a multi-valve implantable strip system designed for anterior chamber angle placement. The device comprises three micro-valves embedded within a biocompatible strip, each engineered to activate at specific intraocular pressure (IOP) thresholds (20–25 mmHg, 30–35 mmHg, and >50 mmHg). This graduated mechanism allows dynamic, staged aqueous outflow that mirrors physiological resistance, aiming to prevent both early hypotony and hypertensive spikes. The concept represents a step forward in personalized glaucoma therapy, with potential applications in both primary open-angle glaucoma and refractory cases. A prototype and preclinical validation roadmap are proposed.

| KEYWORDS
"Malignancy", "Oncology", "AML", "Leukemia", and "Neurology"

| ARTICLE INFORMATION
ACCEPTED: 12 April 2025 **PUBLISHED:** 28 April 2025 **DOI:** 10.32996/jmhs.2024.6.2.10

1. Introduction

Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness globally. The primary modifiable risk factor is elevated intraocular pressure (IOP), and its reduction remains the cornerstone of glaucoma management [1]. Despite the development of pharmacological agents and surgical techniques, challenges persist in achieving sustained IOP control without complications such as hypotony, bleb fibrosis, or implant failure [2,3].

Current surgical options include trabeculectomy, glaucoma drainage devices (Ahmed, Baerveldt), and minimally invasive glaucoma surgeries (MIGS). While effective, these procedures either offer limited pressure modulation or carry significant risks [4]. There is a need for pressure-sensitive devices that offer stage-wise control of aqueous humor outflow.

2. Conceptual Framework

We propose a novel glaucoma drainage system a **multi-strip valve implant** that surgically placed in the **anterior chamber angle (4 to 7 o'clock)** in close proximity to the **trabecular meshwork**. This device consists of three micro-valves embedded within a flexible biocompatible strip.

Design Features**:**

- **Valve 1** opens at IOP > 20–25 mmHg
- **Valve 2** opens at IOP > 30–35 mmHg

- **Valve 3** opens at IOP > 50 mmHg

The implant is intended to lie flush within the anterior chamber angle, minimizing irritation to the corneal endothelium or iris and avoiding the need for sub conjunctival filtration blebs.
This pressure-tiered design provides **gradual, staged aqueous humor outflow**, offering a dynamic response to rising IOP levels and reducing the risk of both early hypotony and IOP spikes.

3. Material and Mechanism

The device will be constructed using **biocompatible elastomeric polymers** (e.g., medical-grade silicone or polyurethane). The micro-valves will employ **MEMS (Micro-Electro-Mechanical Systems)** technology or **smart hydrogels** capable of deforming or opening under specific pressure thresholds [5].

Key attributes include:

- Hydrophilic surface to reduce protein adhesion and inflammation
- Anti-fibrotic coating (e.g., heparin, MMC-release)
- Radiopacity or marker system for post-op imaging

4. Surgical Technique

- **Ab interno approach** via a corneal incision (1.8–2.2 mm)
- Gonioscopic visualization of the angle from 4 to 7 o'clock
- Strip insertion into Schlemm's canal-adjacent angle using a micro-catheter or injector system
- Self-anchoring design or hydrophilic adhesive tabs for stabilization

This technique avoids conjunctival manipulation and is compatible with existing MIGS platforms.

5. Theoretical Advantages

- **Staged IOP control** improves safety profile and mimics physiological drainage
- **Reduces hypotony risk** as initial valve activates only above 20 mmHg
- **Improved longevity** due to reduced fibrosis (no bleb required)
- **Adjustable engineering** allows custom design based on patient risk
- **Expandable to include drug delivery reservoirs** (e.g., anti-scarring agents)

6. Indications for Use

This multi-valve implant designed for a wide range of glaucoma where traditional surgeries are either ineffective or contraindicated. These include:

- **Refractory glaucoma** after failed trabeculectomy or tube shunts
- **Neovascular glaucoma (NVG)** [17]
- **Uveitic glaucoma** [18]
- **Traumatic glaucoma** [19]
- **Pediatric and developmental glaucoma** where adjustable flow is needed [20]
- **Glaucoma associated with ocular syndromes** (e.g., ICE syndrome)

These indications reflect the versatility and adaptability of the pressure-responsive, staged design in managing complex glaucoma cases.

7. Validation Pathway

Preclinical Development Plan:

- **Phase I**: CAD prototyping and bench simulation of valve behavior
- **Phase II**: Flow testing using anterior segment perfusion models
- **Phase III**: Ex vivo validation in cadaveric and animal eyes (rabbit, porcine)
- **Phase IV**: Biocompatibility, cytotoxicity, and animal safety testing per ISO 10993

Clinical Trial Roadmap:

- **Pilot first-in-human (FIH) trial**: 10–20 patients with refractory glaucoma
- **Endpoints**: IOP reduction, complication rate, endothelial cell loss, need for medications

8. Future Directions

This implant opens several avenues for advanced glaucoma management:

- **Smart valve systems** with micro-sensors to monitor real-time IOP [6]

- **Drug-eluting capabilities** to modulate healing response
- **Customizable designs** for pediatric, neovascular, or Uveitic glaucoma

9. Conclusion

This proposed multi-valve glaucoma implant presents a paradigm shift in aqueous humor drainage by offering **pressure-responsive, staged outflow** that mirrors the physiological IOP curve. With a favorable safety profile and scalability across patient types, this device could mark a new chapter in minimally invasive glaucoma surgery.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

Reference

[1] Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–20.
[2] Gedde SJ, Herndon LW, Brandt JD, et al. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153(5):804–14.
[3] Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. Ophthalmology. 2011;118(3):443–51.
[4] Saheb H, Ahmed IIK. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23(2):96–104.
[5] Liang X, Liu C, Wang Y, et al. Advanced microfluidic systems for glaucoma drainage. Lab Chip. 2021;21(5):905–916.
[6] Mansouri K, Medeiros FA, Weinreb RN. Continuous 24-hour intraocular pressure monitoring with a wireless ocular telemetry sensor: initial clinical experience in patients with glaucoma. Ophthalmology. 2012;119(4):671–76.
[7] Francis BA, Singh K, Lin SC, et al. Novel glaucoma procedures: a report by the American Academy of Ophthalmology. Ophthalmology. 2011;118(7):1466–80.
[8] Ting JLW, Damji KF, Stiles MC, et al. Aqueous humor dynamics: a review. Can J Ophthalmol. 2010;45(6):583–90.
[9] Pillunat LE, Erb C, Jünemann AGM, et al. Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents. Clin Ophthalmol. 2017;11:1583–1600.
[10] Kaplowitz K, Schuman JS, Loewen NA. Techniques and outcomes of minimally invasive trabecular ablation and bypass surgery. Br J Ophthalmol. 2014;98(5):579–85.
[11] Pinchuk L, Wilson GJ, Barry JJ, et al. Medical applications of poly(styrene-block-isobutylene-block-styrene) ("SIBS"). Biomaterials. 2008;29(4):448–60.
[12] Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalmol Vis Sci. 1991;32(13):3145–66.
[13] Fea AM. Phacoemulsification versus phacoemulsification with iStent: a prospective, randomized study in patients with primary open-angle glaucoma. J Cataract Refract Surg. 2010;36(3):407–12.
[14] Al Habash A, Ahmed IIK. A novel implantable glaucoma device: surgical technique and outcomes. Middle East Afr J Ophthalmol. 2015;22(1):30–36.
[15] Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–11.
[16] Quaranta L, Riva I, Gerardi C, et al. Quality of life in glaucoma: a review of the literature. Adv Ther. 2016;33(6):959–81.
[17] Netland PA, Ishida K, Boyle JW. The Ahmed glaucoma valve in neovascular glaucoma. Ophthalmology. 2010;117(11):1981–7.
[18] Ozdal PC, Vianna RN, Deschênes J. Ahmed valve implantation in uveitic glaucoma: long-term follow-up. Br J Ophthalmol. 2006;90(6): 681–685.
[19] Amini H, Fakhraie G, Abolfathzadeh N, et al. Ahmed glaucoma valve implantation in eyes with traumatic glaucoma. J Glaucoma. 2008;17(8):654–658.
[20] Beck AD, Freedman S. Novel glaucoma procedures: a report by the American Academy of Ophthalmology. Ophthalmology. 2011;118(7):1466–1480.